Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 20 of 28.
May 2013
27 May · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on May 27, 2013 allotted 9,400 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.9 May · Change in Company Secretary/Compliance Officer
8 May · Dividend
Board of Directors of the Company at its meeting held on May 07, 2013, has recommended dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2012-2013 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
Apr 2013
26 Apr · Board meeting
1. To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2013. 2. To Consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2013.17 Apr · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on April 17, 2013 allotted 42800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Mar 2013
26 Mar · Business
Compensation Committee of the Company, at its meeting held on March 12, 2013 has allotted 25,000 stock options and cancelled 1,70,850 stock options pursuant to ESOS 2003.11 Mar · Business
Operations Committee of the Board of Directors of the Company, at its Meeting held on March 11, 2013 allotted 9,500 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Feb 2013
15 Feb · Disclosure
Operations Committee of the Board of Directors of the Company, at its meeting held on February 15, 2013 allotted 47,200 shares to the employees of the Company on exercise of optios granted to them pursuant to ESOS 2003.
Jan 2013
18 Jan · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2012.16 Jan · Business
Operations Committee of the Board of Directors of the Company, at its meeting held on January 16, 2013 allotted 58,900 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Dec 2012
6 Dec · Business
Operations Committee of the Board of Directors of the Company, at its meeting held on December 06, 2012 allotted 13,100 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Nov 2012
Oct 2012
30 Oct · Business
Board of Directors of the Company, at its Meeting held on October 30, 2012 allotted 9,950 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.19 Oct · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Second Quarter/ Half year ended September 30, 2012.
Sep 2012
27 Sep · Business
Operations Committee of the Board of Directors of the Company, at its Meeting held on September 26, 2012 allotted 22,300 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Aug 2012
29 Aug · Business
Operations Committee of the Board of Directors of the Company, at its Meeting held on August 29, 2012 allotted 43,350 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.8 Aug · Meeting
At the Annual General Meeting held on August 03, 2012 the Shareholders have approved the following : Dividend of Rs. 2/- per share of Re.1 each (200%) on the Equity Share Capital of the Company for the financial year ended 2011-12.2 Aug · Business
Board of Directors of the Company, at its Meeting held on August 02, 2012 allotted 33,500 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Jul 2012
23 Jul · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the quarter ended June 30, 2012.4 Jul · Meeting
Register of Members and the Share Transfer Books of the Company will remain closed from July 23, 2012 to August 03, 2012 (both days inclusive) for the purpose of the Annual Closure for the Annual General Meeting scheduled to be held on August 03, 2012 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting is payable.
Jun 2012
19 Jun · Business
Board of Directors of the Company, at its Operation Committee Meeting held on June 15, 2012 allotted 41,800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
May 2012
8 May · Disclosure
Compensation Committee of the Company at its meeting held on May 07, 2012 has cancelled 2,01,500 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company.8 May · Dividend
Board of Directors of the Company at its meeting held on May 08, 2012 has recommended Dividend @ 200% i.e. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2011-2012 subject to the approval of the Shareholders at the ensuing Annual General Meeting.